Cerity Partners LLC Acquires 2,423 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cerity Partners LLC boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 18.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,548 shares of the biopharmaceutical company’s stock after acquiring an additional 2,423 shares during the quarter. Cerity Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $16,344,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of REGN. SteelPeak Wealth LLC grew its holdings in shares of Regeneron Pharmaceuticals by 173.0% in the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after purchasing an additional 692 shares during the last quarter. Atria Investments Inc increased its position in shares of Regeneron Pharmaceuticals by 12.2% during the first quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock worth $8,317,000 after acquiring an additional 941 shares during the period. Mizuho Securities USA LLC raised its stake in shares of Regeneron Pharmaceuticals by 625.5% during the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after acquiring an additional 51,162 shares in the last quarter. Tri Locum Partners LP boosted its holdings in shares of Regeneron Pharmaceuticals by 104.5% in the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after purchasing an additional 8,949 shares during the period. Finally, Tidal Investments LLC grew its stake in Regeneron Pharmaceuticals by 16.8% in the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock worth $4,774,000 after purchasing an additional 711 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $749.51 on Tuesday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $735.95 and a 12-month high of $1,211.20. The firm has a 50 day moving average of $937.00 and a two-hundred day moving average of $1,025.99. The firm has a market capitalization of $82.36 billion, a PE ratio of 18.55, a P/E/G ratio of 2.84 and a beta of 0.15.

Insider Transactions at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 7.48% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Morgan Stanley lowered their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Oppenheimer lowered their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Finally, BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,099.55.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.